Cargando…
小细胞肺癌免疫治疗疗效预测指标的现状与未来
Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer. However, the survival benefits emerged after three to six months since...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583877/ https://www.ncbi.nlm.nih.gov/pubmed/32773012 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.42 |